See today's BioWorld Asia
To read the full story, subscribe or sign in.

Despite pandemic, Eisai launches two drugs, looks to expand horizons

July 14, 2020
By Gina Lee
HONG KONG – Tokyo-headquartered Eisai Co. Ltd. is targeting new markets for its orexin receptor antagonist, Dayvigo, to treat insomnia.
BioWorld Asia Drugs Neurology/psychiatric Japan